Aligos Therapeutics (FRA:5WK0) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5WK0 Aligos Therapeutics Inc FRA:5WK0
44 GF Score
Price €4.87
GF Value €30.07
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Aligos Therapeutics Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

FRA:5WK0
44GF Score
Aligos Therapeutics Inc FRA:5WK0
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (FRA:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued. The current stock price of €4.87 is trading 83.8% below its estimated GF Value™ of €30.07. GuruFocus considers Aligos Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:5WK0:

  • Total Noninterest Expense:
  • GF Value™: €30.07 vs. price of €4.87 (83.8% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aligos Therapeutics Business Description

Other Exchanges ALGS:USA5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score

Get the complete analysis for FRA:5WK0

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.87
Price
€30.07
GF Value